Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Share-based Compensation (2016 - 2025)

Fate Therapeutics' Share-based Compensation history spans 14 years, with the latest figure at $5.5 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 39.39% year-over-year to $5.5 million; the TTM value through Dec 2025 reached $24.9 million, down 39.94%, while the annual FY2025 figure was $24.9 million, 39.94% down from the prior year.
  • Share-based Compensation reached $5.5 million in Q4 2025 per FATE's latest filing, up from $4.9 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $20.5 million in Q2 2022 to a low of $4.9 million in Q3 2025.
  • Average Share-based Compensation over 5 years is $12.1 million, with a median of $11.4 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: soared 87.7% in 2021, then plummeted 58.68% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $14.6 million in 2021, then skyrocketed by 32.88% to $19.4 million in 2022, then plummeted by 51.14% to $9.5 million in 2023, then dropped by 3.75% to $9.1 million in 2024, then plummeted by 39.39% to $5.5 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Share-based Compensation are $5.5 million (Q4 2025), $4.9 million (Q3 2025), and $7.2 million (Q2 2025).